HAYWARD, Calif., April 26 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer will present at the Deutsche Bank 35th Annual Health Care Conference in Boston, MA on Monday, May 3, 2010 at approximately 9:20 am Eastern Time.
To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.anthera.com. Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.
CONTACT: Juliane Snowden of Burns McClellan, Inc., [email protected]
SOURCE Anthera Pharmaceuticals, Inc.